This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There’s a gap between the supply of digital health tools that hospitals and health systems offer patients, and what patients-as-consumers need for overall health and wellbeing. This chasm is illustrated in The future of the digital patientexperience , the latest report from HIMSS and the Center for Connected Medicine (CCM).
in May and June 2020. Top-line, Accenture points to four pillars on which the pharma industry can “reinvent its relevance,” as the report title suggests: To express greater empathy, understanding the patientexperience of delaying treatment, financial impacts, and mental health challenges the pandemic has caused.
trillion in 2020, as the bubble chart illustrates. Whether looking at biotech beauty and what “clean” really means, effectively dealing with obesity, or biohacking our biology, wellness-engaged health citizens are not interesting in the shiny new thing without data backing up claims.
in 2020, with projections suggesting up to 70% of clinical trials incorporating wearable sensors by 2025. The company will supply solutions to AstraZeneca while extending services to pharma, biotech companies, and clinical research organizations. In a recent review paper appeared on Nature , Mittermaier et al. in 2010 to 11.4%
Four years ago, when we launched our first bio fund, the idea that software would make an impact in drug discovery sounded like science fiction; the idea it could transform the patientexperience in healthcare a fool’s errand. Tech, biotech, and our healthcare system are merging—into what we call simply “bio”.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content